<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30142825</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>04</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>34</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma.</ArticleTitle>            <Pagination>                <MedlinePgn>e11970</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000011970</ELocationID>            <Abstract>                <AbstractText>The aim of the present study was to meta-analyze the literature on the diagnostic value of 18-fluorodeoxyglucose (F-FDG) positron emission tomography (PET) with or without computed tomography (CT) in detecting extrahepatic metastases or local residual/recurrent hepatocellular carcinoma (HCC).Systematic review of literature in MEDLINE, Embase, and Cochrane databases was conducted in March 2017, and relevant studies analyzing the diagnostic performance of F-FDG PET with or without CT were meta-analyzed.Meta-analysis was carried out on data from 11 studies involving 572 patients. F-FDG PET, with or without CT, showed pooled sensitivity of 64% and pooled specificity of 95%. Pooled sensitivity was similar with CT (74%) or without (52%; P = .279). Similarly, pooled specificity was comparable with CT (93%) or without 95% (P = .481).F-FDG PET, with or without CT, shows relatively low sensitivity but high specificity for diagnosing extrahepatic metastases or local residual/recurrent HCC. Adding CT to F-FDG PET may improve diagnostic performance, but the available evidence suggests that the improvement is not statistically significant.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Liao</LastName>                    <ForeName>Xiaoli</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of First Chemotherapy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wei</LastName>                    <ForeName>Junbao</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Therapeutic Radiology.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Yongqiang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of First Chemotherapy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhong</LastName>                    <ForeName>Jianhong</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Hepatobiliary Surgery Department.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Zhihui</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Department of First Chemotherapy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liao</LastName>                    <ForeName>Sina</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of First Chemotherapy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Qian</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of First Chemotherapy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wei</LastName>                    <ForeName>Changyuan</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D017418">Meta-Analysis</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0Z5B2CJX4D</RegistryNumber>                <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Nucl Med. 2003 Jun;17(4):261-79</RefSource>                <PMID Version="1">12932109</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1285-9</RefSource>                <PMID Version="1">16802155</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2015 Jul;56(7):995-1002</RefSource>                <PMID Version="1">25952733</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hepatogastroenterology. 2003 Nov-Dec;50(54):2154-6</RefSource>                <PMID Version="1">14696485</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>World J Hepatol. 2009 Oct 31;1(1):90-7</RefSource>                <PMID Version="1">21160970</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Hepatol. 2000 May;32(5):792-7</RefSource>                <PMID Version="1">10845666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hepatobiliary Pancreat Dis Int. 2008 Jun;7(3):237-57</RefSource>                <PMID Version="1">18522878</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Oncol (R Coll Radiol). 2008 Apr;20(3):234-40</RefSource>                <PMID Version="1">18155453</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 1997 Jul 19;350(9072):185-6</RefSource>                <PMID Version="1">9250191</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Clin Oncol. 2014 Dec;19(6):1020-8</RefSource>                <PMID Version="1">24366329</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Vasc Interv Radiol. 2006 Mar;17(3):505-12</RefSource>                <PMID Version="1">16567675</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2005 Nov-Dec;25(6C):4719-25</RefSource>                <PMID Version="1">16334166</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Control Clin Trials. 1986 Sep;7(3):177-88</RefSource>                <PMID Version="1">3802833</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Dig Dis. 2013 Aug;14(8):433-8</RefSource>                <PMID Version="1">23615075</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 1995 Oct;36(10):1811-7</RefSource>                <PMID Version="1">7562048</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gut. 2002 Oct;51(4):459-62</RefSource>                <PMID Version="1">12235060</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Epidemiol Rev. 1987;9:1-30</RefSource>                <PMID Version="1">3678409</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2003 Sep 6;327(7414):557-60</RefSource>                <PMID Version="1">12958120</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oral Oncol. 2016 Jan;52:11-7</RefSource>                <PMID Version="1">26547126</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2007 Jun;48(6):902-9</RefSource>                <PMID Version="1">17504862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Gastroenterol. 1999 Nov;94(11):3314-9</RefSource>                <PMID Version="1">10566736</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Hepatol. 2003 Feb;38(2):200-7</RefSource>                <PMID Version="1">12547409</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6208-14</RefSource>                <PMID Version="1">15448009</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Epidemiol. 2005 Sep;58(9):882-93</RefSource>                <PMID Version="1">16085191</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):468-82</RefSource>                <PMID Version="1">19838700</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biostatistics. 2007 Apr;8(2):239-51</RefSource>                <PMID Version="1">16698768</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Med Res Methodol. 2003 Nov 10;3:25</RefSource>                <PMID Version="1">14606960</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):427-33</RefSource>                <PMID Version="1">17255262</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2012 Jan;13(1):e11-22</RefSource>                <PMID Version="1">22047762</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Nucl Med. 2004 Jul;34(3):209-23</RefSource>                <PMID Version="1">15202102</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Radiology. 2000 Feb;214(2):349-57</RefSource>                <PMID Version="1">10671580</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg. 2014 Aug;260(2):329-40</RefSource>                <PMID Version="1">24096763</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29</RefSource>                <PMID Version="1">25559415</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2014 Oct;35(10):9459-68</RefSource>                <PMID Version="1">25119592</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Scand J Gastroenterol. 2014 Jun;49(6):649-61</RefSource>                <PMID Version="1">24716523</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hepatogastroenterology. 2009 Jul-Aug;56(93):1111-6</RefSource>                <PMID Version="1">19760952</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Radiol. 2012 Sep;81(9):2417-22</RefSource>                <PMID Version="1">21899970</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nucl Med. 2008 Dec;49(12):1912-21</RefSource>                <PMID Version="1">18997056</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Gastroenterol. 2004 Oct;39(10):961-8</RefSource>                <PMID Version="1">15549449</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Liver Transpl. 2010 Jun;16(6):767-72</RefSource>                <PMID Version="1">20517911</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</RefSource>                <PMID Version="1">21296855</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2007 Dec;18(6):1469-73</RefSource>                <PMID Version="1">17982632</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2000 Jun 16;275(24):18489-94</RefSource>                <PMID Version="1">10764804</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nan Fang Yi Ke Da Xue Xue Bao. 2006 Aug;26(8):1087-91, 1095</RefSource>                <PMID Version="1">16939890</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30142825</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000011970</ArticleId>            <ArticleId IdType="pii">00005792-201808240-00077</ArticleId>            <ArticleId IdType="pmc">PMC6112887</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>